Loading...
•
Dec 31, 2020
Wave Life Sciences Q4 2020 Earnings Report
Financial results for the fourth quarter and full year were announced and a business update was provided.
Key Takeaways
Wave Life Sciences reported a net loss of $28.8 million in the fourth quarter of 2020, compared to a net loss of $56.8 million in the same period in 2019. The company's cash runway is expected to extend into the second quarter of 2023.
Advanced five clinical programs and novel ADAR editing modality in 2021.
Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease on track for end of 1Q 2021.
Moving towards first patient dosing in three clinical trials with pipeline candidates incorporating PN chemistry: WVE-003 (SNP3), WVE-004 (C9orf72) and WVE-N531 (Exon 53).
Cash runway expected into 2Q 2023.
Forward Guidance
Wave expects that its existing cash and cash equivalents, together with expected and committed cash from its existing collaboration, will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...